Pathogenesis of Spinal Muscular Atrophy

被引:0
|
作者
Claus, P. [1 ,2 ]
机构
[1] Hannover Med Sch, Inst Neuroanat, D-30625 Hannover, Germany
[2] Zentrum Syst Neurowissensch, Hannover, Germany
关键词
Rho-Kinase; actin; motoneuron; growth factor; DETERMINING GENE-PRODUCT; MOTOR-NEURON PROTEIN; MOTONEURON PROTEIN; NEURITE OUTGROWTH; GROWTH CONES; SMN; SURVIVAL; LOCALIZATION; COMPLEXES; PROFILIN;
D O I
10.1055/s-0032-1316308
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Spinal muscular atrophy (SMA) in its most severe form (type 1) is a lethal neurodegenerative disease in children. It represents the most frequent genetic cause of death in this patient group and has a prevalence of 1: 5 000 live births. Aa yet there are no options for therapy. SMA is caused by a mutation or, respectively, deletion of the survival motoneuron 1 gene (Smn1) and proceeds through degeneration of motor neurons in the spinal cord. The SMN protein presumably has various functions: it serves as a platform for the formation of pre-mRNA splicing complexes - this splicing process takes place in the cell nucleus. Furthermore, SMN also plays a role in the axons of nerve cells. Preliminary work in our group has demonstrated that SMN regulates the growth of neurites and that in SMA there is a dysregulation of the actin cytoskeleton. The biochemical signalling pathway responsible for this dysregulation has been identified. It involves the rho-kinase (ROCK) signalling pathway - an important switch for various neuronal, actin-dependent processes. The ROCK molecule is thus also a suitable target molecule for pharmacological interventions.
引用
收藏
页码:203 / 205
页数:3
相关论文
共 50 条
  • [21] SPINAL MUSCULAR-ATROPHY - NEW THOUGHTS ON THE PATHOGENESIS AND CLASSIFICATION SCHEMA
    RUSSMAN, BS
    IANNACONE, ST
    BUNCHER, CR
    SAMAHA, FJ
    WHITE, M
    PERKINS, B
    ZIMMERMAN, L
    SMITH, C
    BURHANS, K
    BARKER, L
    JOURNAL OF CHILD NEUROLOGY, 1992, 7 (04) : 347 - 353
  • [22] Pathogenesis-targeting therapeutics for spinal and bulbar muscular atrophy (SBMA)
    Suzuki, Keisuke
    Kastuno, Masahisa
    Banno, Haruhiko
    Sobue, Gen
    NEUROPATHOLOGY, 2009, 29 (04) : 509 - 516
  • [23] Pathogenesis, animal models and therapeutics in Spinal and bulbar muscular atrophy (SBMA)
    Katsuno, Masahisa
    Adachi, Hiroaki
    Waza, Masahiro
    Banno, Haruhiko
    Suzuki, Keisuke
    Tanaka, Fumiaki
    Doyu, Manabu
    Sobue, Gen
    EXPERIMENTAL NEUROLOGY, 2006, 200 (01) : 8 - 18
  • [24] Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy (SBMA)
    Banno, Haruhiko
    Katsuno, Masahisa
    Suzuki, Keisuke
    Tanaka, Fumiaki
    Sobue, Gen
    CELL AND TISSUE RESEARCH, 2012, 349 (01) : 313 - 320
  • [25] Spinal muscular atrophy
    Chokri, M.
    Salma, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [26] Spinal Muscular Atrophy
    Nicolau, Stefan
    Waldrop, Megan A.
    Connolly, Anne M.
    Mendell, Jerry R.
    SEMINARS IN PEDIATRIC NEUROLOGY, 2021, 37
  • [27] Spinal muscular atrophy
    Talbot, K
    JOURNAL OF INHERITED METABOLIC DISEASE, 1999, 22 (04) : 545 - 554
  • [28] Spinal muscular atrophy
    Martin, Pascal
    Horber, Veronka
    Park, Joohyun
    Kronlage, Cornelius
    Grimm, Alexander
    NERVENARZT, 2022, 93 (02): : 191 - 200
  • [29] Spinal Muscular Atrophy
    Kolb, Stephen J.
    Kissel, John T.
    NEUROLOGIC CLINICS, 2015, 33 (04) : 831 - +
  • [30] Spinal muscular atrophy
    Eugenio Mercuri
    Charlotte J. Sumner
    Francesco Muntoni
    Basil T. Darras
    Richard S. Finkel
    Nature Reviews Disease Primers, 8